Wedbush Downgrades TCR2 Therapeutics (TCRR) to Neutral, Following Clinical Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TCRR Hot Sheet
Price: $1.48 --0%
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded TCR2 Therapeutics (NASDAQ: TCRR) from Outperform to Neutral with a price target of $11.00 (from $45.00).
For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.
Shares of TCR2 Therapeutics closed at $15.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Vistra Energy (VST) to Sector Weight
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- BTIG Downgrades Driven Brands (DRVN) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
